Biogen, Inc. (BIIB)

164.42 -4.15 (-2.46%) USD  |  NASDAQ  |  Jan 16, 16:00
167.60 +3.18 (+1.93%) After-Hours: 20:00
More

Biogen Current Deferred Revenue (Per Share)

Current Deferred Revenue (Per Share) Chart

View Current Deferred Revenue (Per Share) for BIIB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Current Deferred Revenue (Per Share) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Current Deferred Revenue (Per Share) Range, Past 5 Years

View Current Deferred Revenue (Per Share) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Current Deferred Revenue (Per Share) Benchmarks

View Current Deferred Revenue (Per Share) Benchmarks
Start Trial
Eli Lilly & Co. --
AbbVie, Inc. --
Stoke Therapeutics, Inc. Upgrade
Alnylam Pharmaceuticals, Inc. Upgrade
Insmed, Inc. --